French biotech Inventiva's lead drug stumbles in systemic sclerosis study, ahead of NASH readout
France’s Inventiva (Euronext: $IVA) has suffered its first big setback following its public listing in 2017. The company’s lead experimental drug, lanifibranor, failed a mid-stage trial in patients with a form of systemic sclerosis (SSc) — a rare, chronic life-threatening disorder in which the immune system attacks its own organs and is characterized by a buildup of scar tissue — prompting the Daix-based drug developer to abandon the program for the indication.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.